Korsgaard S, Noring U, Gerlach J
Psychopharmacology (Berl). 1984;84(1):76-9. doi: 10.1007/BF00432029.
Fluperlapine, a new clozapine-like neuroleptic drug with weak affinity for dopamine receptors, was evaluated in a blind, placebo controlled trial in 11 patients with stable hyperkinesia (ten with tardive dyskinesia (TD) and one with spontaneous dyskinesia). Drug effects during active treatment (200-600 mg/day) and during pre- and post-treatment placebo periods were determined by scoring randomly sequenced videotapes of TD and parkinsonian symptoms recorded weekly during standardized examinations. TD score was unchanged, while parkinsonism slightly decreased (P less than 0.05) and eye-blinking rates increased (P less than 0.05). Psychiatric symptoms showed no significant changes, although positive psychotic symptoms diminished in four patients. Side effects included dizziness, sedation and constipation. The effects in movement disorders found in this study may imply that fluperlapine is less liable than traditional neuroleptics to induce acute extrapyramidal side effects and tardive dyskinesia and is particularly beneficial in the treatment of patients vulnerable to neurological side-effects.
氟哌拉平是一种新型的类似氯氮平的抗精神病药物，对多巴胺受体亲和力较弱。在一项针对11例稳定型运动亢进患者（10例迟发性运动障碍患者和1例自发性运动障碍患者）的双盲、安慰剂对照试验中对其进行了评估。通过对标准化检查期间每周记录的迟发性运动障碍和帕金森症状的随机排序录像带进行评分，确定了积极治疗期间（200 - 600毫克/天）以及治疗前和治疗后安慰剂期间的药物效果。迟发性运动障碍评分未变，而帕金森症状略有减轻（P < 0.05），眨眼率增加（P < 0.05）。精神症状无显著变化，尽管4例患者的阳性精神病性症状有所减轻。副作用包括头晕、镇静和便秘。本研究中发现的对运动障碍的影响可能意味着，与传统抗精神病药物相比，氟哌拉平诱发急性锥体外系副作用和迟发性运动障碍的可能性较小，对易出现神经副作用的患者治疗尤其有益。
